IDEAYA Biosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

21.08.23	IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705) (PR Newswire)
16.08.23	IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma (PR Newswire)
10.08.23	IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
02.08.23	IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors (PR Newswire)
01.08.23	IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event (PR Newswire)
28.07.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
30.06.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
22.06.23	IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy (PR Newswire)
12.06.23	IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types (PR Newswire)
30.05.23	IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events (PR Newswire)
26.05.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
22.05.23	IDEAYA: FDA Approves To Proceed With Evaluation Of IDE397 In Combination With AMG 193 (RTTNews)
22.05.23	IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors (PR Newswire)
16.05.23	IDEAYA Announces Amended Clinical Trial Collaboration And Supply Agreements With Pfizer (RTTNews)
16.05.23	IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma (PR Newswire)
09.05.23	IDEAYA Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
01.05.23	IDEAYA Biosciences to Participate in Upcoming May 2023 Investor Relations Event (PR Newswire)
28.04.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
27.04.23	IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
25.04.23	IDEAYA Announces Pricing of Public Offering (PR Newswire)
24.04.23	IDEAYA Announces Proposed Public Offering of Common Stock (PR Newswire)
24.04.23	IDEAYA Reports Positive Interim Phase 2 Data For Darovasertib, Crizotinib Combination (RTTNews)
23.04.23	IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line M... (PR Newswire)
19.04.23	IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors (PR Newswire)
03.04.23	IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event (PR Newswire)
31.03.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
14.03.23	IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First-in-Class Synthetic Lethality Programs IDE397 (MAT2A), IDE161 (PARG) and Werner Helicase (PR Newswire)
07.03.23	IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update (PR Newswire)
01.03.23	IDEAYA Biosciences to Participate in Investor Conferences in March 2023 (PR Newswire)
16.02.23	IDEAYA Biosciences to Participate in Citi's 2023 Virtual Oncology Leadership Summit (PR Newswire)
01.02.23	IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference (PR Newswire)
23.01.23	IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma (PR Newswire)
09.01.23	IDEAYA's IDE161 IND Gets FDA Clearance To Proceed To Phase 1 Clinical Trial In Solid Tumors (RTTNews)
09.01.23	IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161 (PR Newswire)
03.01.23	IDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 (PR Newswire)
19.12.22	IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board (PR Newswire)
12.12.22	IDEAYA Submits IND Application For Phase 1/2 Trial To Evaluate IDE161 (RTTNews)
12.12.22	IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161 (PR Newswire)
05.12.22	IDEAYA: Darovasertib+ Crizotinib Combination Therapy Gets FDA Fast Track Designation For MUM (RTTNews)
05.12.22	IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma (PR Newswire)
29.11.22	IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R&D Day Webcast on Monday, December 12, 2022 (PR Newswire)
28.11.22	IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer (RTTNews)
28.11.22	IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline (PR Newswire)
08.11.22	IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
01.11.22	IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences (PR Newswire)
18.10.22	IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors (PR Newswire)
19.09.22	IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
15.09.22	IDEAYA Biosciences Drops 10% After Pricing Public Offering Of Shares (RTTNews)
15.09.22	Pre-market Movers: ATXG, FWBI, IDYA, ENOB, LUCY… (RTTNews)
15.09.22	IDEAYA Biosciences Prices Underwritten Public Offering Of 7.62 Mln Shares At $10.50/shr (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu IDEAYA Biosciences Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten